Jet-injection assisted photodynamic therapy for superficial and nodular basal cell carcinoma: A pilot study.
basal cell carcinoma
jet‐injector
nodular basal cell carcinoma
photodynamic therapy
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
revised:
02
04
2024
received:
19
02
2024
accepted:
21
04
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
Photodynamic therapy (PDT) with topical δ-Aminolevulinic acid (ALA) has efficacy in treating basal cell carcinoma (BCC) but is limited by incomplete penetration of ALA into the deeper dermis. This prospective open-label pilot trial investigated the safety and efficacy of photosensitizer jet injection for PDT (JI-PDT) for BCC treatment. It was performed with 15 patients (n = 15) with histologically confirmed, untreated, low-risk nodular BCCs at a single institution. For the intervention, JI-PDT patients (n = 11) received two sessions of jet-injected ALA with PDT separated by four to 6 weeks. To further understand treatment technique, another group of patients (n = 4) received jet-injected ALA followed by tumor excision and fluorescence microscopy (JI-E). Treatment tolerability was assessed by local skin responses (LSR) score at five distinct time intervals. Fluorescence microscopy assessed protoporphyrin IX penetration depth and biodistribution within the tumor. At the primary endpoint, tumor clearance was evaluated via visual inspection, dermoscopy and reflectance confocal microscopy. Postinjection and postillumination pain levels, and patient satisfaction, were scored on a 0-10 scale. Fifteen participants with mean age of 58.3, who were 15/15 White, non-Hispanic enrolled. The median composite LSR score immediately after JI-PDT was 5 (interquartile range [IQR] = 3) which decreased to 0.5 (IQR = 1) at primary endpoint (p < 0.01). Immunofluorescence of excised BCC tumors with jet-injected ALA showed photosensitizer penetration into papillary and reticular dermis. Of the 13 JI-PDT tumors, 11 had tumor clearance confirmed, 1 recurred, and 1 was lost to follow-up. 1/11 patients experienced a serious adverse event of cellulitis. 70% of patients had local scarring at 3 months. Patients reported an average pain level of 5.6 (standard deviation [SD] = 2.3) during jet injection and 3.7 (SD = 1.8) during light illumination. Jet injection of ALA for PDT treatment of nodular low-risk BCC is tolerable and feasible and may represent a novel modality to improve PDT.
Sections du résumé
BACKGROUND
BACKGROUND
Photodynamic therapy (PDT) with topical δ-Aminolevulinic acid (ALA) has efficacy in treating basal cell carcinoma (BCC) but is limited by incomplete penetration of ALA into the deeper dermis. This prospective open-label pilot trial investigated the safety and efficacy of photosensitizer jet injection for PDT (JI-PDT) for BCC treatment. It was performed with 15 patients (n = 15) with histologically confirmed, untreated, low-risk nodular BCCs at a single institution.
METHODS
METHODS
For the intervention, JI-PDT patients (n = 11) received two sessions of jet-injected ALA with PDT separated by four to 6 weeks. To further understand treatment technique, another group of patients (n = 4) received jet-injected ALA followed by tumor excision and fluorescence microscopy (JI-E). Treatment tolerability was assessed by local skin responses (LSR) score at five distinct time intervals. Fluorescence microscopy assessed protoporphyrin IX penetration depth and biodistribution within the tumor. At the primary endpoint, tumor clearance was evaluated via visual inspection, dermoscopy and reflectance confocal microscopy. Postinjection and postillumination pain levels, and patient satisfaction, were scored on a 0-10 scale.
RESULTS
RESULTS
Fifteen participants with mean age of 58.3, who were 15/15 White, non-Hispanic enrolled. The median composite LSR score immediately after JI-PDT was 5 (interquartile range [IQR] = 3) which decreased to 0.5 (IQR = 1) at primary endpoint (p < 0.01). Immunofluorescence of excised BCC tumors with jet-injected ALA showed photosensitizer penetration into papillary and reticular dermis. Of the 13 JI-PDT tumors, 11 had tumor clearance confirmed, 1 recurred, and 1 was lost to follow-up. 1/11 patients experienced a serious adverse event of cellulitis. 70% of patients had local scarring at 3 months. Patients reported an average pain level of 5.6 (standard deviation [SD] = 2.3) during jet injection and 3.7 (SD = 1.8) during light illumination.
CONCLUSIONS
CONCLUSIONS
Jet injection of ALA for PDT treatment of nodular low-risk BCC is tolerable and feasible and may represent a novel modality to improve PDT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : LEO Pharma
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
NCCN. NCCN Guidelines Basal Cell Skin Cancer Version 1.2019. 2019.
Drucker AM, Adam GP, Rofeberg V, Gazula A, Smith B, Moustafa F, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta‐analysis. Ann Intern Med. 2018;169(7):456–466.
Wong TH, Morton CA, Collier N, Haylett A, Ibbotson S, McKenna KE, et al. British association of dermatologists and British photodermatology group guidelines for topical photodynamic therapy 2018. Br J Dermatol. 2019;180(4):730–739.
Haedersdal M, Erlendsson AM, Paasch U, Anderson RR. Translational medicine in the field of ablative fractional laser (AFXL)‐assisted drug delivery: a critical review from basics to current clinical status. J Am Acad Dermatol. 2016;74(5):981–1004.
Barolet D, Benohanian A. Current trends in needle‐free jet injection: an update. Clin Cosmet Investig Dermatol. 2018;11:231–238.
Gong Y, Labh S, Jin Y, Diao HY, Li XL, Liu ZY, et al. Needle‐free injection of 5‐aminolevulinic acid in photodynamic therapy for the treatment of non‐melanoma skin cancer. Dermatol Ther. 2016;29(4):255–262.
Campanati A, Giuliodori K, Giuliano A, Martina E, Ganzetti G, Marconi B, et al. Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach. Arch Dermatol Res. 2013;305(8):691–697.
Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser‐assisted photodynamic therapy for actinic keratosis: a systematic review and meta‐analysis. J Am Acad Dermatol. 2019;80(4):947–956.
Evangelou G, Koumaki D, Fragiadaki I, Chaniotis V, Farrar MD, Karatzi C, et al. Intralesional photodynamic therapy induces apoptosis in basal cell carcinoma and bowen's disease through caspase 3 and granzyme B. J Eur Acad Dermatol Venereol. 2023;37(7):1311–1317.
van Delft LCJ, Nelemans PJ, Kessels JPHM, Kreukels H, Roozeboom MH, de Rooij MJM, et al. Long‐Term efficacy of photodynamic therapy with fractionated 5‐Aminolevulinic acid 20% versus conventional Two‐Stage topical methyl aminolevulinate for superficial Basal‐Cell carcinoma. Dermatology. 2022;238(6):1044–1049.
Zeng Q, Chen C, Chen D, Zhang G, Wang X. Non‐surgical therapeutic strategies for non‐melanoma skin cancers. Curr Treat Options Oncol. 2023;24(12):1978–1993.
Erlendsson AM, Haedersdal M, Rossi AM. Needle‐free injection assisted drug delivery‐histological characterization of cutaneous deposition. Lasers Surg Med. 2020;52(1):33–37.
Morton CA, McKenna KE, Rhodes LE, the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159(6):1245–1266.
Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, et al. Distribution of 5‐aminolevulinic acid‐induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol. 1995;62(5):906–913.
Sandberg C, Halldin CB, Ericson MB, Larko O, Krogstad A‐L, Wennberg A‐M. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol. 2008;159(5):1170–1176.
Monfrecola G, Procaccini EM, D'Onofrio D, Roberti G, Liuzzi R, Staibano S, et al. Hyperpigmentation induced by topical 5‐aminolaevulinic acid plus visible light. J Photochem Photobiol, B. 2002;68(2–3):147–155.
Nestor MS, Han H, Ceci FM, Lawson A, Gade A. Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. J Cosmet Dermatol. 2023;22(9):2471–2475.
Chen M, Zhou A, Khachemoune A. Photodynamic therapy in treating a subset of basal cell carcinoma: strengths, shortcomings, comparisons with surgical modalities, and potential role as adjunctive therapy. Am J Clin Dermatol. 2024;25(1):99–118.
Mazur E, Kwiatkowska D, Reich A. Photodynamic therapy in pigmented basal cell Carcinoma‐A review. Biomedicines. 2023;11(11):3099.
Yu N, Wu L, Su J, Chen M, Lu L, Huang K, et al. Photodynamic therapy combined with surgery versus Mohs micrographic surgery for the treatment of difficult‐to‐treat basal cell carcinoma: a retrospective clinical study. J Dermatol Treat. 2023;34(1):2200871.